Pegfilgrastim Biosimilars Market Estimations (2025 - 2035)
The pegfilgrastim biosimilars market covers biosimilars referencing Neulasta (pegfilgrastim), a long-acting G-CSF, in prefilled syringes, autoinjectors and on-body injectors, for prevention of febrile neutropenia in patients receiving myelosuppressive chemotherapy and for acute radiation syndrome, supplied to hospitals, oncology clinics and pharmacies.
📄Report ID:2523
|
📊Format: Databook
|
📅Published: 19 November 2026
|
⚡Delivery: Immediate